Turning Complexity into Consistency: De-risked Solutions for CAR T Development and Manufacturing

• Establishing a robust, platform-based approach to T-cell process and analytical development to accelerate progression from development to GMP manufacturing while improving reliability and reproducibility
• Delivering high-titer, consistent LVV supply while eliminating complex transient transfection to enable scalable, reliable production with low replication-competent lentivirus risk 
• Leveraging this integrated platform to enable lean technology transfer, a high rate of successful batch release, accelerate timelines, and deliver patient-ready outcomes

Speakers:

Francesca Vitelli

Global Vice President, Head Of Process Analytical Development & Innovation

Minaris Advanced Therapies